Literature DB >> 23312294

Epstein-Barr virus-encoded latent membrane protein-1 upregulates 14-3-3σ and Reprimo to confer G(2)/M phase cell cycle arrest.

Kok-Siong Yeo1, Taznim Begam Mohd Mohidin, Ching-Ching Ng.   

Abstract

Epstein-Barr virus (EBV) is a ubiquitous tumor-causing virus which infects more than 90% of the world population asymptomatically. Recent studies suggest that LMP-1, -2A and -2B cooperate in the tumorigenesis of EBV-associated epithelial cancers such as nasopharygeal carcinoma, oral and gastric cancer. In this study, LMPs were expressed in the HEK293T cell line to reveal their oncogenic mechanism via investigation on their involvement in the regulation of the cell cycle and genes that are involved. LMPs were expressed in HEK293T in single and co-expression manner. The transcription of cell cycle arrest genes were examined via real-time PCR. Cell cycle progression was examined via flow cytometry. 14-3-3σ and Reprimo were upregulated in all LMP-1 expressing cells. Moreover, cell cycle arrest at G(2)/M progression was detected in all LMP-1 expressing cells. Therefore, we conclude that LMP-1 may induce cell cycle arrest at G(2)/M progression via upregulation of 14-3-3σ and Reprimo.
Copyright © 2012 Académie des sciences. Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23312294     DOI: 10.1016/j.crvi.2012.11.002

Source DB:  PubMed          Journal:  C R Biol        ISSN: 1631-0691            Impact factor:   1.583


  2 in total

Review 1.  Cell cycle regulation during viral infection.

Authors:  Sumedha Bagga; Michael J Bouchard
Journal:  Methods Mol Biol       Date:  2014

2.  Inverse expression of survivin and reprimo correlates with poor patient prognosis in gastric cancer.

Authors:  Paulina Cerda-Opazo; Manuel Valenzuela-Valderrama; Ignacio Wichmann; Andrés Rodríguez; Daniel Contreras-Reyes; Elmer A Fernández; Gonzalo Carrasco-Aviño; Alejandro H Corvalán; Andrew F G Quest
Journal:  Oncotarget       Date:  2018-02-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.